drugset / Trial / NCT00368329

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

NCT00368329

Phase 1 Terminated 4 enrolled Stanford University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To study the safety and feasibility of stereotactic radiation dose escalation following neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating the acute and late toxicity of treatment.

Timeline

Start
2006-06
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 825 mg/m2 Oral
Subject Carboplatin Small molecule 2 unknown Intravenous
Subject Fluorodeoxyglucose Diagnostic / imaging agent 5 mbq Intravenous
Subject Fluorodeoxyglucose Diagnostic / imaging agent 10 mbq Intravenous
Subject fluorouracil Small molecule 200 mg/m2 Intravenous